Leptin promotes the proliferative response and invasiveness in human endometrial cancer cells by activating multiple signal-transduction pathways

Endocrine-Related Cancer

Volumn 13, Issue 2, 2006, Pages 629-640

  Sharma, D ^a   Saxena, N K ^a   Vertino, P M ^a   Anania, F A ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; JANUS KINASE; LEPTIN; MITOGEN ACTIVATED PROTEIN KINASE 1; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PROTEIN KINASE B; STAT3 PROTEIN;

ARTICLE; CANCER GROWTH; CANCER RISK; CELL CULTURE; CELL INVASION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG INHIBITION; ENDOMETRIUM CANCER; FEMALE; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; OBESITY; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; SIGNAL TRANSDUCTION; STATISTICAL ANALYSIS; WESTERN BLOTTING;

CELL PROLIFERATION; ENDOMETRIAL NEOPLASMS; ENZYME ACTIVATION; FEMALE; HUMANS; JANUS KINASE 1; LEPTIN; MITOGEN-ACTIVATED PROTEIN KINASE 1; NEOPLASM INVASIVENESS; OBESITY; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 33745108419     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.1.01169     Document Type: Article

References (47)

1. Abu-Abid S, Szold A & Klausner J 2002 Obesity and cancer. Journal of Medicine 33 73-86.
2. Ahima RS & Osei SY 2004 Leptin signaling. Physiology and Behavior 81 223-241.
3. Bahrenberg G, Behrmann I, Barthel A, Hekerman P, Heinrich PC, Joost HG & Becker W 2002 Identification of the critical sequence elements in the cytoplasmic domain of leptin receptor isoforms required for janus kinase/signal transducer and activator of transcription activation by receptor heterodimers. Molecular Endocrinology 16 859-872.
4. Bjorbaek C, Uotani S, da Silva B & Flier JS 1997 Divergent signaling capacities of the long and short isoforms of the leptin receptor. Journal of Biological Chemistry 272 32686-32695.
5. Bjorbaek C, Elmquist JK, Frantz JD, Shoelson SE & Flier JS 1998 Identification of SOCS-3 as a potential mediator of central leptin resistance. Molecular Cell 1 619-625.
6. Bjorbaek C, El-Haschimi K, Frantz JD & Flier JS 1999 The role of SOCS-3 in leptin signaling and leptin resistance. Journal of Biological Chemistry 274 30059-30065.
7. Bouloumie A, Drexler HC, Lafontan M & Busse R 1998 Leptin, the product of Ob gene, promotes angiogenesis. Circulation Research 83 1059-1066.
8. Bowman T, Garcia R, Turkson J & Jove R 2000 STATs in oncogenesis. Oncogene 19 2474-2488.
9. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J & Greenberg ME 1999 Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96 857-868.
10. Burdelya L, Catlett-Falcone R, Levitzki A, Cheng F, Mora LB, Sotomayor E, Coppola D, Sun J, Sebti S, Dalton WS et al. 2002 Combination therapy with AG-490 and interleukin 12 achieves greater antitumor effects than either agent alone. Molecular Cancer Therapy 1 893-899.
11. Calle EE, Rodriquez C, Walker-Thurmond K & Thun MJ 2003 Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. New England Journal of Medicine 348 1625-1638.
12. Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, Frisch S & Reed JC 1998 Regulation of cell death protease caspase-9 by phosphorylation. Science 282 1318-1321.
13. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernandez-Luna JL, Nunez G et al. 1999 Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10 105-115.
14. Choi JH, Park SH, Leung PC & Choi KC 2005 Expression of leptin receptors and potential effects of leptin on the cell growth and activation of mitogen-activated protein kinases in ovarian cancer cells. Journal of Clinical Endocrinology and Metabolism 90 207-210.
15. Del Peso L, Gonzalez-Garcia M, Page C, Herrera R & Nunez G 1997 Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 278 687-689.
16. Emilsson V, Arch JR, de Groot RP, Lister CA & Cawthorne MA 1999 Leptin treatment increases suppressors of cytokine signaling in central and peripheral tissues. FEBS Letters 455 170-174.
17. Franke T, Kaplan D & Cantley L 1997 PI3K: downstream AKT blocks apoptosis. Cell 88 435-437.
18. Grandis JR, Drenning SD, Chakraborty A, Zhou MY, Zeng Q, Pitt AS & Tweardy DJ 1998 Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor-mediated cell growth in vitro. Journal of Clinical Investigation 102 1385-1392.
19. Halaas JL, Gajiwala KS, Maffei M, Cohen SL, Chait BT, Rabinowitz D, Lallone RL, Burley SK & Friedman JM 1995 Weight reducing effects of the plasma protein encoded by the obese gene. Science 269 543-546.
20. Houseknecht KL, Mantzoros CS, Kuliawat R, Hadro E, Flier JS & Kahn BB 1996 Evidence for leptin binding to proteins in serum of rodents and humans: modulation with obesity. Diabetes 45 1638-1643.
21. Hu L, Zaloudek C, Mills GB, Gray J & Jaffe RB 2000 In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3′-kinase inhibitor (LY294002). Clinical Cancer Research 6 880-886.
22. Hu X, Juneja SC, Maihle NJ & Cleary MP 2002 Leptin-A growth factor in normal and malignant breast cells and for normal mammary gland development. Journal of the National Cancer Institute 94 1704-1711.
23. Huang L & Li C 2000 Leptin: a multifunctional hormone. Cell Research 10 81-92.
24. Jin X, Gossett DR, Wang S, Yang D, Cao Y, Chen J, Guo R, Reynolds RK & Lin J 2004 Inhibition of AKT survival pathway by a small molecule inhibitor in human endometrial cancer cells. British Journal of Cancer 91 1808-1812.
25. Kaaks R, Lukanova A & Kurzer MS 2002 Obesity, endogenous hormones and endometrial cancer risk: A synthetic review. Cancer Epidemiology, Biomarkers and Prevention 11 1531-1543.
26. Kulik G, Klippel A & Weber MJ 1997 Antiapoptotic signaling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. Molecular and Cellular Biology 17 1595-1606.
27. MacDougald OA, Hwang CS, Fan H & Lane MD 1995 Regulated expression of the obese gene product (leptin) in white adipose tissue and 3T3-L1 adipocytes. PNAS 92 9034-9037.
28. Mareel M & Leroy A 2003 Clinical, cellular and molecular aspects of cancer invasion. Physiology Reviews 83 337-376.
29. Matsuzawa Y, Funahashi T & Nakamura T 1999 Molecular mechanism of metabolic syndrome X: contribution of adipocytokines adipocyte-derived bioactive substances. Annals of the New York Academy of Sciences 892 146-154.
30. Meydan N, Grunberger T, Dadi H, Shahar M, Arpaia E, Lapidot Z, Leeder JS, Freedman M, Cohen A, Gazit A et al. 1996 Inhibition of acute lymphoblastic leukemia by a Jak-2 inhibitor. Nature 379 645-648.
31. Mueck AO & Seeger H 2004 Hormone therapy after endometrial cancer. Endocrine-Related cancer 11 305-314.
32. Pai R, Lin C, Tran T & Tarnawski A 2005 Leptin activates STAT and ERK2 pathways and induces gastric cancer cell proliferation. Biochemical and Biophysical Research Communications 331 984-992.
33. Pap M & Cooper G 1998 Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-kinase/akt cell survival pathway. Journal of Biological Chemistry 273 19929-19932.
34. Petridou E, Belechri M, Dessypris N, Koukoulomatis P, Diakomanolis E, Spanos E & Trichopoulos D 2002 Leptin and body mass index in relation to endometrial cancer risk. Annals of Nutrition and Metabolism 46 147-151.
35. Rose DP, Komninou D & Stephenson GD 2004 Obesity, adipocytokines, and insulin resistance in breast cancer. Obesity Reviews 5 153-165.
36. Satyaswaroop PG & Tabibzadeh SS 1991 Extracellular matrix and the patterns of differentiation of human endometrial carcinomas in vitro and in vivo. Cancer Research 51 5661-5666.
37. Sierra-Honigmann MR, Nath AK, Murakami C, Garcia-Cardena G, Papapetropoulos A, Sessa WC, Madge LA, Schechner JS, Schwabb MB, Polverini PJ et al. 1998 Biological action of leptin as an angiogenic factor. Science 281 1683-1686.
38. Sinha MK, Opentanova I, Ohannesian JP, Kolaczynski JW, Heiman ML, Hale J, Becker GW, Bowsher RR, Stephens TW & Caro JF 1996 Evidence of free and bound leptin in human circulation. Studies in lean and obese subjects and during short-term fasting. Journal of Clinical Investigation 98 1277-1282.
39. Somasundar P, Yu AK, Vona-Davis L & McFadden DW 2003 Differential effects of leptin on cancer in vitro. Journal of Surgical Research 113 50-55.
40. Somasundar P, Frankenberry KA, Skinner H, Vedula G, McFadden DW, Riggs D, Jackson B, Vangilder R, Hileman SM & Vona-Davis LC 2004a Prostate cancer cell proliferation is influenced by leptin. Journal of Surgical Research 118 71-82.
41. Somasunder P, McFadden DW, Hileman SM & Vona-Davis L 2004b Leptin is a growth factor in cancer. Journal of Surgical Research 116 337-349.
42. Song H, Wang R, Wang S & Lin J 2005 A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. PNAS 102 4700-4705.
43. Stephenson GD & Rose DP 2003 Breast cancer and obesity: An update. Nutrition and Cancer 45 1-16.
44. Su JD, Mayo LD, Donner DB & Durden DL 2003 PTEN and phosphatidylinositol 3′-kinase inhibitors up-regulate p53 and block tumor-induced angiogenesis: Evidence for an effect on the tumor and endothelial compartment. Cancer Research 63 3585-3592.
45. Tartaglia LA 1997 The leptin receptor. Journal of Biological Chemistry 272 6093-6096.
46. Vollmer G 2003 Endometrial cancer: experimental models useful for studies on molecular aspects of endometrial cancer and carcinogenesis. Endocrine-Related Cancer 10 23-42.
47. Yuan SS, Tsai KB, Chung YF, Chan TF, Yeh YT, Tsai LY & Su JH 2004 Aberrant expression and possible involvement of the leptin receptor in endometrial cancer. Gynecologic Oncology 92 769-775.